Biodexa Pharmaceuticals Plc ADR (BDRX)

$6.70 -1.15 (-14.65%)
Market Cap 28.69M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 112,300
Avg Vol 321,602
Day's Range N/A - N/A
Shares Out 3.65M
Stochastic %K 23%
Beta 1.17
Analysts Strong Sell
Price Target $180.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
Jspence0427
Jspence0427 Aug. 1 at 10:19 PM
$BDRX what’s this things deal?
0 · Reply
DaSqueeza
DaSqueeza Aug. 1 at 9:37 PM
$BDRX big run incoming!
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX need to tighten your leash ,ore u r perky
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX i must finish few things xcur for now etc
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX not quite yet beud u r being impatient please
0 · Reply
Najoua233902
Najoua233902 Aug. 1 at 6:53 PM
$BDRX $GVH $CDT last call last call 😂🤣
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 6:02 PM
$BDRX gonna have a back and forth as she sets up slowly
0 · Reply
Vulnerable
Vulnerable Aug. 1 at 5:40 PM
$BDRX $PSTV reliable mo, always lower.
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Aug. 1 at 5:30 PM
$BDRX buy
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 5:29 PM
$BDRX modifying the mid to upper 8;s
0 · Reply
Latest News on BDRX
ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 2 days ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 5 days ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 17 days ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 19 days ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 5 weeks ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 5 weeks ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 5 weeks ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 6 weeks ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 7 weeks ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 2 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 2 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 2 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 2 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 2 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 3 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 4 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 4 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 5 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 5 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 5 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 6 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 6 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 6 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 6 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 9 months ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 9 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 9 months ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 10 months ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 10 months ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Oct 4, 2024, 8:30 AM EDT - 10 months ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

Sep 26, 2024, 8:30 AM EDT - 11 months ago

Interim results for the six months ended June 30, 2024

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Aug 30, 2024, 4:30 PM EDT - 1 year ago

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jspence0427
Jspence0427 Aug. 1 at 10:19 PM
$BDRX what’s this things deal?
0 · Reply
DaSqueeza
DaSqueeza Aug. 1 at 9:37 PM
$BDRX big run incoming!
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX need to tighten your leash ,ore u r perky
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX i must finish few things xcur for now etc
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 8:28 PM
$BDRX not quite yet beud u r being impatient please
0 · Reply
Najoua233902
Najoua233902 Aug. 1 at 6:53 PM
$BDRX $GVH $CDT last call last call 😂🤣
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 6:02 PM
$BDRX gonna have a back and forth as she sets up slowly
0 · Reply
Vulnerable
Vulnerable Aug. 1 at 5:40 PM
$BDRX $PSTV reliable mo, always lower.
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Aug. 1 at 5:30 PM
$BDRX buy
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 5:29 PM
$BDRX modifying the mid to upper 8;s
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 5:26 PM
$BDRX utilizing the 5's ranges 1st for now
1 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 5:25 PM
$BDRX accumlated sorry for that will have multiple moves to get out and get in etc for larger pop
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 5:25 PM
$BDRX accumulate for a move coming up off these ranges
0 · Reply
BULLNATION1
BULLNATION1 Aug. 1 at 5:15 PM
$BDRX CEO I know you read stocktwits, you lost our blessing and will suffer and will take all shareholders down with you.
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 1 at 4:25 PM
$BDRX coding your afterhours
1 · Reply
Darkswede
Darkswede Aug. 1 at 3:47 PM
$BDRX Your ADR for Biodexa had a reverse split yesterday and they charged you a $300 management fee for it.
0 · Reply
prakritim
prakritim Aug. 1 at 3:33 PM
$BDRX buying in 3s. below 6 is free fall.
0 · Reply
DaSqueeza
DaSqueeza Aug. 1 at 8:27 AM
$BDRX high short squeeze possibility !! L2 thin to the upside!!
0 · Reply
upNupAlways3
upNupAlways3 Aug. 1 at 3:54 AM
$BDRX give it a couple a days! Low floats have been popular lately! It’s a know runner, pump n dump, but we’re not here for long term!
0 · Reply
BossTrade
BossTrade Aug. 1 at 3:14 AM
$BDRX I lost track of all the reverse splits since I got out of this. Damn.
0 · Reply
ahTony
ahTony Jul. 31 at 10:42 PM
$BDRX float under 500k after yesterday's RS.
1 · Reply
Najoua233902
Najoua233902 Jul. 31 at 9:07 PM
$GVH added $BDRX $CDT
0 · Reply